Search
Researchers developed ALADYNOULLI, a Bayesian generative framework that jointly analyzes longitudinal electronic health records, age, and polygenic risk, identifying 21 reproducible disease features and improving disease prediction performance.
Analyze how regulatory pressure, demand explosion, and drug repurposing are reshaping R&D investment strategies and the market landscape for biopharmaceutical companies.
In the third quarter of 2026, the FDA will make approval decisions on multiple biotechnology products, involving areas such as IgA nephropathy, mRNA influenza vaccines, Duchenne muscular dystrophy cell therapy, and gene therapy. These decisions will profoundly impact the direction of the medical technology industry.
ZS Impact Institute report shows 90% of consumers trust AI health advice as much as that of doctors, early diagnosis could save $500 billion, promoting a zero-distance care model.
This week brought multiple major news in the biotechnology industry: Parabilis Medicines set a record with a $770.5 million IPO, Merck entered into a collaboration with Protillion worth up to $510 million for AI-driven drug discovery, a Lassa fever-rabies dual vaccine entered human trials, and CRISPR and mRNA delivery platforms demonstrated potential in treating cancer and Duchenne muscular dystrophy, respectively. These events reflect the accelerating convergence of capital, artificial intelligence, and gene editing technologies in medical innovation.
A recent Nature review points out that mRNA technology is moving from a vaccine tool toward a broader therapeutic platform. As bottlenecks around delivery, immune silencing, and tissue targeting are being addressed, the industry is entering the “mRNA therapeutics 2.0” phase.